Multiple Blue Cross Blue Shield (BCBS) affiliate plans have issued positive coverage determinations for the EndoPredict test from Myriad Genetics Inc, Salt Lake City, including Blue Cross and Blue Shield of Kansas, Blue Cross and Blue Shield of Kansas City, BlueCross BlueShield of South Carolina, Horizon Blue Cross Blue Shield of New Jersey, and Independence Blue Cross.

The positive BCBS decisions will provide coverage for an additional 12 million patients in the United States.

EndoPredict is a second-generation, multigene test that is designed to predict disease recurrence in patients diagnosed with breast cancer.

Johnathan Lancaster, MD, PhD, Myriad Genetic Laboratories.

Johnathan Lancaster, MD, PhD, Myriad Genetic Laboratories.

“We are excited to see that payors are increasingly recognizing the level and quality of clinical evidence supporting the EndoPredict test for patients with breast cancer,” says Johnathan M. Lancaster, MD, PhD, chief medical officer at Myriad Genetic Laboratories. “EndoPredict ‘markedly outperformed’ the first-generation test in a large, head-to-head study recently presented at the San Antonio Breast Cancer Symposium in December. We are confident that EndoPredict will provide improved health outcomes and value for both patients and payors.”

The coverage decisions follow a recent positive review by Evidence Street, which provides technical assessments of medical technologies for the Blue Cross Blue Shield Association. Affiliated plans of the association insure one in three Americans. Evidence Street’s review found that the EndoPredict test results in a meaningful improvement in the net health outcomes in node-negative breast cancer patients.

In aggregate, payors in the United States now cover the EndoPredict test for more than 32 million patients. Myriad previously announced plans to launch EndoPredict in the United States in the first half of calendar year 2017. EndoPredict is marketed outside the United States and has been used to guide treatment selection for more than 13,000 patients.

For more information, visit Myriad Genetics.